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Eff ect of 3-year folic acid supplementation on cognitive 
function in older adults in the FACIT trial: a randomised, 
double blind, controlled trial 
Jane Durga, Martin P J van Boxtel, Evert G Schouten, Frans J Kok, Jelle Jolles, Martijn B Katan, Petra Verhoef
Summary
Background Low folate and raised homocysteine concentrations in blood are associated with poor cognitive 
performance in the general population. As part of the FACIT trial to assess the eﬀ ect of folic acid on markers of 
atherosclerosis in men and women aged 50–70 years with raised plasma total homocysteine and normal serum 
vitamin B12 at screening, we report here the fi ndings for the secondary endpoint: the eﬀ ect of folic acid supplementation 
on cognitive performance.
Methods Our randomised, double blind, placebo controlled study took place between November, 1999, and December, 
2004, in the Netherlands. We randomly assigned 818 participants 800 µg daily oral folic acid or placebo for 3 years. 
The eﬀ ect on cognitive performance was measured as the diﬀ erence between the two groups in the 3-year change in 
performance for memory, sensorimotor speed, complex speed, information processing speed, and word fl uency. 
Analysis was by intention-to-treat. This trial is registered with clinicaltrials.gov with trial number NCT00110604.
Findings Serum folate concentrations increased by 576% (95% CI 539 to 614) and plasma total homocysteine 
concentrations decreased by 26% (24 to 28) in participants taking folic acid compared with those taking placebo. The 
3-year change in memory (diﬀ erence in Z scores 0·132, 95% CI 0·032 to 0·233), information processing speed 
(0·087, 0·016 to 0·158) and sensorimotor speed (0·064, –0·001 to 0·129) were signifi cantly better in the folic acid 
group than in the placebo group.  
Interpretation Folic acid supplementation for 3 years signifi cantly improved domains of cognitive function that tend 
to decline with age. 
Introduction
Cognitive function declines with ageing, especially 
cognitive domains related to memory and information 
processing speed.1 Changes in cognitive performance, 
especially memory function, have been linked to risk of 
dementia in old age.2,3 Modifi able risk factors for age-
related cognitive decline have been identifi ed, but their 
causality has not yet been established.4 Poor folate status 
is one such suspected risk factor.5,6 
A longitudinal study,7 undertaken in the USA when 
folic acid fortifi cation of foods was routine, showed 
greater cognitive decline in people with a high folic acid 
intake than in those with low intakes. A systematic 
review of supplementation with folic acid alone or in 
combination with other B vitamins showed that no 
benefi cial eﬀ ect on cognitive performance was con-
ferred.8 Many of the trials have used small study 
populations, supplemented for a short duration, or used 
tests such as the Mini-Mental State Examination,9  which 
are unable to detect subtle changes in cognitive function 
(table 1).10–19 
We investigated whether 800 µg daily oral folic acid 
supplementation for 3 years improved cognitive per-
formance compared with placebo in older adults. 
Cognitive performance was assessed with tests that 
probe cognitive domains that decline in the ageing 
process. 
Methods
Participants
Participants were men and post-menopausal women aged 
50–70 years, from the Gelderland region in the Netherlands 
who participated in the Folic Acid and Carotid Intima-
media Thickness (FACIT) trial (unpublished), a study 
investigating the eﬀ ect of folic acid supplementation on 
atherosclerotic progression. Additional outcomes of the 
trial were age-related decline in cognitive function and 
hearing. Here we present data for the eﬀ ect of folic acid on 
the cognitive performance aspect of the study. 
We used municipal and blood-bank registries to recruit 
participants. On the assumption that high concentrations 
of plasma total homocysteine were a risk factor for vascular 
disease, we selected participants expected to benefi t from 
folic acid’s homocysteine-lowering eﬀ ect and excluded 
participants with concentrations of plasma total 
homocysteine of less than 13 μmol/L (73% of those 
screened). We excluded participants with raised 
homocysteine concentrations (>26 µmol/L) that were 
possibly due to factors other than suboptimal folate 
concentrations, including: serum vitamin B12 concentration 
of less than 200 pmol/L (10% of those screened); self-
reported medical diagnosis of renal or thyroid disease; or 
self-reported use of medications that infl uence folate 
metabolism.20 Additionally, we excluded participants with 
self-reported intestinal disease and participants who 
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reportedly used B-vitamin supplements or drugs that could 
aﬀ ect atherosclerotic progression. Finally, more than 80% 
self-reported compliance during a 6-week placebo run-in 
period was required. The Wageningen University medical 
ethics committee approved the study and participants gave 
written informed consent. 
Procedures
After the initial measurement sessions, participants were 
allocated placebo or 800 µg per day folic acid, which is 
regarded as a low dose for a clinical trial. Patients were 
allocated treatment or placebo with permuted blocks of 
sizes four and six, which varied randomly. Specialised staﬀ  
who were not involved in the study allocated and labelled 
the capsule boxes with participants’ unique sequence 
number. Participants in the same household received the 
same treatment. The folic acid and placebo capsules, 
produced by Swiss-Caps Benelux (Heerhugowaard, 
Netherlands), were indistinguishable in appearance. 
Capsules were individually packaged in foil strips 
containing 28 capsules per strip, with the days of the week 
printed on the back. Every year, participants received a 
13-month supply of capsules. Compliance was judged by 
capsule-return counts and a diary that registered missed 
capsules. Diaries and capsules were returned by 
participants every 12 weeks.
At the end of the study, the proportion of participants 
who thought they had received folic acid or placebo did not 
diﬀ er between the two groups (p=0·64). 70% of participants 
in the folic acid group and 71% in the placebo group 
thought they had been allocated folic acid; whereas 11% in 
the folic acid group and 9% in the placebo group thought 
Duration Number at 
follow-up 
(in 
analyses)
Mean 
age, 
years, 
SD)
Population type Dose of folic 
acid (dose of 
placebo), 
mg per day
Types of cognitive test Conclusion
Folic acid only
Fioravanti 
et al10
60 days 29 80 (6) Patients with memory complaints, 
Mini-Mental State Examination 
score between 16 and 24, mild to 
moderate cognitive decline on basis 
of Global Deterioration Score, 
70–90 years, serum folate <7 nmol/L
15 1 Randt Memory Test
a Acquistion and recall
b Delayed recall
c Memory index
d Encoding factor 
e Cognitive effi  ciency
f Attention effi  ciency 
Folic acid improved attention effi  ciency 
score (p<0·05). 
When taking into account baseline folate 
status, folic acid improved acquisition and 
recall (p<0·007), delayed recall (p<0·007), 
memory index (p<0.002), encoding 
(p<0·005).
Sommer et al11 10 weeks 7 77 (4) Patients meeting DSM-III-R criteria 
for dementia, ≥65 years, 
suboptimal folate (serum folate 
2–5 ng/mL, red-blood-cell 
folate 127–452 ng/mL), 
B12 >200 pg/mL 
2x10 1 Wechsler Memory Scale
1a Logical memory subtest
1b Associate learning subtest
2 Boston Naming test
3 Controlled Oral Word Association test
4 Trail making test
5 Finger Tapping test
6 Wechsler Adult Intelligence Scale-
revised (composite of information, 
vocabulary and similarities sub-tests)
7 Benton Visual Retention test
Folic acid seemed to reduce performance on 
associate learning subtest of Wechsler 
Memory Scale (p=0·08) and Trails B 
(p=0·08). 
Folic acid with other B vitamins
Eussen et al12 24 weeks 162 82 (5) Mini-Mental State Examination ≥ 
19, ≥70 years, suboptimal vitamin 
B12 status (B12 100–200 pmol/L or 
B12 200–300 pmol/L, 
methylmalonic acid ≥0·32 µmol/L, 
creatinine ≤120 µmol/L) 
0·4 Domains based on clustering of similar 
tests
1 Attention
2 Construction
3 Sensomotor speed
4 Memory
5 Executive function
Compared with placebo or to vitamin B12 
only. No eff ect of folic acid on cognitive 
domains.
McMahon et al13 2 years 253 74 (6) ≥65 years, homocysteine 
≥13 µmol/L
1 1 Mini-Mental State Examination
2 Wechsler Paragraph Recall 
3 Category Word Fluency
4 Rey Auditory Verbal Learning
4a composite of trials 1-5
4b trial 7
5 Raven’s Progressive Matrices
6 Controlled Oral Word Association
7 Reitan Trail Making, part B
8 Composite score of all tests 
General trend towards reduced performance 
on tests. In crude analyses signifi cance was 
reached for the Reitan Trail Making test part 
B) (7% slower, 95% CI 2 to 13%) and Wechsler 
Paragraph Recall test (mean diff erence –1·19, 
95% CI –2·30 to –0·04).  
After adjustment for baseline performance, 
sex, and education, the composite score of 
all tests was lower in the folic acid group 
than in the placebo group (–0·11, 95% CI 
–0·22 to 0·00).
Stott et al 14 1 year 167 75 (6) Mini-Mental State Examination ≥ 
19, ischaemic vascular disease, 
≥65 years, red-blood-cell folate 
≥280 ng/mL, vitamin B12 
≥250 pg/mL
2·5 1 Telephone Interview for Cognitive 
Status
2 Letter Digit Coding 
No eff ect
(Continues on next page)
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they had been allocated placebo. All staﬀ , including all 
authors, were unaware of group assignment until 
completion of the trial and after data analyses.
We assessed cognitive function using fi ve separate tests 
used in the Maastricht Aging Study.21 These fi ve tests were 
used to construct fi ve a-priori-defi ned cognitive domains: 
memory, sensorimotor speed, complex speed, information 
processing speed, and word fl uency.22 Descriptions of the 
tests are in panel 1.23–27 Although not part of the cognitive 
tests used for our study outcome, we used the Mini-Mental 
State Examination9 to screen for participants with possible 
dementia, defi ned as a score of less than 24 points. 
All participants underwent the measurements after an 
overnight fast, followed by a glass of fruit juice and a bread 
product for breakfast. Two trained research assistants 
oversaw the tests during a 40-min session; they used 
standard wording to instruct participants. A third research 
assistant periodically observed the testing to ensure that 
the two research assistants did not deviate from the 
protocol. All cognitive tests were done in the same room 
with the same props. We repeated cognitive testing at the 
end of the study using variations of the tests used at 
baseline (parallel versions). We repeated the verbal fl uency 
test because the validity of a parallel version of the animal-
naming part of the test has not been established.
Fasting venous blood was processed and samples were 
stored at –80ºC. We measured serum folate, erythrocyte 
folate, serum vitamin B12, plasma total homocysteine, 
plasma vitamin B6, serum creatinine, and lipids as 
described elsewhere.22 The C677T polymorphism in the 
gene encoding methylenetrahydrofolate reductase 
(MTHFR)28 and apolipoprotein E genotype were 
determined by PCR of DNA and restriction digestion with 
HinFl and Hha1, respectively. 
Self-reported medical history, including current drug 
use and smoking habits, were ascertained by questionnaire 
(Continued from previous page)
Bryan et al15 5 weeks 104 51 (20) Healthy women 0·75 1 Boxes test
2 Digit Symbol Coding, 120 s
3 Symbol search
4 Digit Span Backward
5 Letter-Number Sequencing
6 Rey Auditory-Verbal Learning test
6a Immediate recall
6b Delayed recall
7 Digit Symbol Coding, symbol recall
8 Activity recall
9 Stroop test
10 Self-ordered pointing task
11 Uses for common objects
12 Trail Making test
13 Verbal Fluency test
14 Excluded Letter Fluency
15 Wechsler Adult Intelligence Scale -
III Vocabulary
16 Spot-the-Word test
Folic acid reduced Verbal Fluency 
performance (p<0·05).
When stratifying by age, folic acid improved 
Rey Auditory-Verbal Learning test 
(recognition task) in older participants 
(>65 years, p<0·05).
Toole et al16 2 years 3097 66 (10) Previous stroke, homocysteine 
>~9 µmol/L
2·5 or 0·02 1 Mini-Mental State Examination No eff ect
Vital Trial 
Collaborative 
Group17
12 weeks 128 Range 
56·89
Mini-Mental State Examination 
score 12–26 or mild cognitive 
impairment assessed by 
modifi ed Telephone Interview 
of Cognitive Status
2 1 Mini-Mental State Examination
2 Alzheimer’s Disease Assessment Scale 
(cognitive part)
No eff ect
Lewerin et al18 4 months 171–179 76 (4) Community-dwelling 0·8 1 Digit Span Forward
2 Digit Span Backward 
3 Identical forms
4 Visual reproduction
5 Synonyms
6 Block design
7 Digit Symbol, 90s
8 Thurstone’s Picture Memory test
9 Figure Classifi cation
Folic acid improved performance on identical 
forms and synonyms (p<0·05).
Obeid et al19 45 days 69 80 (6) Mini-Mental State Examination 
score >15, >65 years 
5·0 orally or 1·1 
(intravenously 
three times a 
week for 
3 weeks)
1 Structured Interview for Diagnosis of 
Dementia of Alzheimer Type, Multi-
infarct Dementia and Dementia 
2 Orientation abilities
3 Memory 
4 Intellectual abilities 
No treatment eff ect reported, only 
diff erences in performance within groups 
DSM-III-R=Diagnostic and Statistical manual of Mental Disorders, 3rd edition revised.
Table 1: Summary of randomised controlled trials examining eff ect of folic-acid-containing supplements on cognitive function
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and reviewed by a research assistant with the participant. 
Education was grouped according to highest attained 
level.29 Height and weight were measured and body-mass 
index calculated. Blood pressure was measured with an 
automated meter (Dinamap Compact Pro 100, General 
Electric). Eight blood-pressure measurements were taken 
and the average calculated. We used a food-frequency 
questionnaire to estimate dietary folate intake during the 
past 3 months.
We measured genotype and attained educational level 
at the beginning of the study. Plasma total homocysteine, 
serum folate, and vitamin B12 concentrations and 
information about medical status and drug use were 
recorded yearly and all other measurements were taken 
at the beginning and end of the study.
Statistical analyses
Our sample size calculation was based on the mean intima-
media thickness progression of the common carotid artery 
(the primary endpoint of the FACIT trial). We assumed 
that if the progression of the mean carotid intima-media 
were 0·01 mm (SD 0·06 mm), then 251 participants would 
be needed in each group to detect a diﬀ erence of 0·015 mm 
(power 80%, two-sided α=0·05). We assumed that 30–40% 
of the population could be lost to follow-up. 
The cognitive domains were constructed with Z scores 
(panel 2).21 Sensorimotor speed measures basic speed, and 
shows direct stimulus-response connections with little 
central processing, whereas complex speed measures time 
needed for higher-order information processing. As other 
investigators have done,30,31 we present global cognitive 
function (an average of the domains). The test scores at 
the beginning and end of the study were pooled to calculate 
the grand mean and SD per test; this information was 
used to calculate the Z scores (panel 2). At baseline, one 
participant missed 50% or more of the subtests for 
complex speed and three participants did not have an 
information processing speed score. These participants 
were assigned the median score of these domains of the 
total population at baseline. 17 participants lost to follow-
up were assigned the median test score of the total 
population at the end of the study. Analyses were done on 
an intention-to-treat basis with SPSS 11.0. No adjustments 
were made for multiple testing. 
The outcome of this study was the diﬀ erence between 
the folic acid and placebo groups in the 3-year change in 
performance for memory, sensorimotor speed, complex 
speed, information-processing speed, and word fl uency. 
We used the t test to determine whether the change in 
cognitive performance diﬀ ered between treatment 
groups. We did all analyses without knowledge of follow-
up folate or homocysteine concentrations. The treatment 
code was broken once an independent statistician had 
verifi ed the data and all authors had formally approved 
the tables showing the main eﬀ ects. 
In secondary analyses, we determined whether the eﬀ ect 
of folic acid supplementation was dependent on initial 
concentrations of folate or homocysteine or MTHFR 
C677T genotype. We determined the eﬀ ect of folic acid 
Panel 1: Description of cognitive function tests
Word learning test23
Measures the storage and retrieval of newly acquired verbal information. Participants were 
instructed to memorise 15 commonly used monosyllabic words. The words were printed on a 
card and were presented in a fi xed sequence for 2 s. Immediately after the 15 words are 
presented, the participants are asked to recall the words. This procedure was done three times. 
20 min after presentation of the words, participants were prompted to recall the 15 words. 
The maximum and total number of correctly repeated words of the immediate recall tests 
were recorded, as well as the number of correctly repeated words in the delayed recall test.
Concept shifting test24
A timed test with four subtests that measure the ease of switching between two 
psychological concepts. Each subtest was printed on one sheet of paper, which contained 
16 circles (15 mm diameter) arranged in a larger circle (16 cm diameter). For the fi rst subtest, 
participants were asked to cross off  the circles in numerical and alphabetical order (eg, 1, A, 2, 
B, 3, C, etc). 
Stroop colour-word test25
Measures selective attention and susceptibility to behavioural interference and consists of 
three subtests. Each subtest was presented on a separate sheet containing four rows of ten 
columns of colour names of coloured blocks. For the fi rst subtest, participants were instructed 
to read words printed in black ink (words were “red”, “blue”, “green”, and “yellow”). 
Participants were asked to name coloured blocks in the second subtest, for the fi nal subtest, 
participants were asked to name the colour of the ink, rather than read the word (eg, say blue 
when the word “RED” was printed in blue ink).
Verbal fl uency test26
Measures word fl uency or the ability to draw on one’s encyclopaedic memory in a strategic 
manner. Participants were asked to name as many animals as possible in 1 min. This test 
indicated the amount of organisation among clusters of related words (eg, pets, zoo animals, 
etc).
Letter digit substitution test27
Assesses general speed of visual information processing. Nine diff erent letters were assigned 
a unique number (1–9) in a key at the top of the form. The participants were presented with a 
random series of letters in cells and were instructed to add the corresponding digit to the 
letters. The number of correctly copied corresponding digits in 90 s was recorded.
Panel 2: Construction of cognitive domains with Z-scores
Memory=(Z15-Word Learning test ‘total immediate recall’+Z15-Word Learning Test ‘maximum immediate recall’+Z15-Word Learning Test ‘delayed recall’)/3
Sensorimotor speed=-(ZConcept Shifting test ‘empty’+ZConcept Shifting test ‘numbers’+ZConcept Shifting test ‘letters’+ZStroop Color-Word test ‘word reading’)/4
Complex speed=-(ZConcept Shifting test ‘numbers and letters’+ZStroop Color-Word test ‘naming ink color’)/2
Information processing speed=ZLetter Digit Substitution test
Word fl uency= ZVerbal Fluency test
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supplementation per stratum (median cut-oﬀ ) using an 
independent sample t test. We used linear regression 
models to examine whether the diﬀ erence in treatment 
eﬀ ects between strata was signifi cant. 
Role of the funding source
The sponsors had no role in the design or implementation 
of the study, data collection, data management, data 
analysis, data interpretation, or in the preparation, review, 
or approval of the manuscript. The corresponding author 
had full access to all the data in the study and had fi nal 
responsibility for the decision to submit for publication.
Results
Patients were randomised between November, 1999, and 
April, 2001, and the study was undertaken from September, 
2000, to December, 2004. The fi gure shows the trial profi le. 
Five participants allocated folic acid treatment reported 
adverse events: forgetfulness, sun allergies, weight gain, 
tinnitus, and dark urine. Adverse eﬀ ects reported in the 
placebo group (n=7) were muscle aches, headaches, weight 
gain, queasiness, bitter taste in mouth, and skin irritations. 
The participant with headache complaints dropped out of 
the trial prematurely. 17 participants (2%) did not return 
for the cognitive function measurements after 3 years, and 
six participants stopped treatment prematurely. The 
proportion of participants lost to follow-up or who stopped 
treatment early did not diﬀ er between the groups (p=0·25). 
Apart from these participants, the compliance of the 
participants was high, with 99% of the capsules reportedly 
consumed. Table 2 shows baseline clinical characteristics 
of the participants.
In both groups, plasma total homocysteine concen-
trations at baseline were lower than at screening, a likely 
result of regression to the mean (table 3). After 3 years, 
serum folate concentrations were signifi cantly higher in 
the folic acid group than in the placebo group (table 3).
Baseline scores on the cognitive tests and domains were 
similar between the two groups (table 4). At baseline, one 
participant in the folic acid group and six in the placebo 
group scored less than 24 points on the Mini-Mental State 
Examination (p=0·85). Whereas sensori motor speed, 
information-processing speed, and complex speed declined 
signifi cantly during the 3-year study in the placebo group, 
 5775 questionnaires returned
 4694 invited based on eligibility
 4200 venepunctures
 494 withdrew
 55 withdrew
 16 withdrew
 406 assigned folic acid  413 assigned placebo 
 405 intended to treat  413 intended to treat
 405 included in the analyses  413 included in the analyses
 907 invited on basis of eligibility
 852 entered placebo run-in period
 18 excluded (compliance <80% or 
  no desire to participate)
 819 randomised
 4 died
 1 lost to follow-up
 3 stopped taking pills
40 000 questionnaires sent out
 1081 excluded
 438 drug use
 243 HRT
 101 self-reported disease
  (thyroid, intestinal, kidney, 
  or cancer)
 90 not yet menopausal
 209 not willing to discontinue B
  vitamin supplementation or
  comply with study protocol
 3293 excluded*
 3044 <13 µmol/L homocysteine 41
  >26 µmol/L homocysteine
 415 <200 pmol/L vitamin B12
     41 
 1 excluded (refused to undergo
  cognitive testing)
 8 died
 4 lost to follow-up
 4 stopped taking pills
Figure: Trial profi le
HRT=hormone replacement therapy. *Participants might have been excluded for multiple reasons. 
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the rate of decline was slower in these domains in the folic 
acid group (table 5). Both groups improved on memory 
tests, because of procedural learning eﬀ ects. However, the 
improvement was signifi cantly greater in the folic acid 
group than in the placebo group.
The 3-year change in cognitive function was signifi cantly 
better in the folic acid group than in the placebo group in 
terms of information-processing speed. Folic acid did not 
aﬀ ect sensorimotor speed, complex speed, or word fl uency. 
Global cognitive function, defi ned as the average of the fi ve 
domains, improved signifi cantly (table 5). Performance on 
the Mini-Mental State Exam ination was not aﬀ ected by 
folic acid group (p=0·63). The median score for both 
groups after 3 years was 29 points (IQR 28–30) ranging 
from 21 to 30 points in the folic acid and 16 to 30 points in 
the placebo group.
In addition to memory and information-processing 
speed, sensorimotor speed improved signifi cantly (p<0·05) 
when other imputation techniques were used (eg, last 
value carried forward, expectation maximisation), when 
17 participants lost to follow-up were excluded from the 
analyses, and when seven participants with initial Mini-
Mental State Examination scores of less than 24 points 
were excluded from the analyses. Finally, at baseline, a 
greater proportion of participants with a low educational 
level, an important determinant of cognitive performance, 
were randomised into the folic acid group. Additionally, a 
higher proportion of participants in the folic acid group 
had dyslipidaemia and self-reported vascular disease. Our 
results did not change when we adjusted for these 
variables. 
51 participants received the same treatment and lived in 
the same households. Hence these observations were not 
independent of one another. When partners were excluded 
from the analyses, the results did not change, except that 
folic acid supplementation signifi cantly improved 
sensorimotor speed (diﬀ erence in Z scores 0·079 [95% CI 
0·014–0·145]).
To show the relevance of our fi ndings we compared the 
regression coeﬃ  cient of age—adjusted for sex, education, 
and treatment calculated with linear regression models 
with initial performance as the dependent variable—with 
the treatment eﬀ ect. 3-year folic acid supplementation 
confers an individual the performance of someone 
4·7 years younger for memory (95% CI 1·1–8·3), 1·7 years 
younger for sensorimotor speed (–0·04 to 3·4), 2·1 years 
younger for information processing speed (0·4–3·7), and 
1·5 years younger for global cognitive function (0·1–2·8). 
Of our test battery, memory—specifi cally delayed 
memory—is the most clinically relevant test. We showed 
that 3-year folic acid supplementation improved per-
formance on the delayed recall sub-test of the 15 word 
learning test by 0·47 words (95% CI 0·14–0·79, p=0·005). 
This improvement is similar to a performance of an 
individual 6·9 years younger (95% CI 2·1–11·8). 
The eﬀ ect of folic acid supplementation was not modifi ed 
by initial folate status or MTHFR C677T genotype. 
Compared with placebo, participants with initial plasma 
total homocysteine concentrations greater than the 
population median of 12·9 µmol/L showed a greater 
improvement in information processing speed than 
participants with concentrations lower than the population 
median (interaction term p=0·034). Information-
processing speed of the latter group improved by 0·013, 
(95% CI -0·086 to 0·111), whereas participants with 
higher homocysteine concentrations improved by 0·166, 
(0·064–0·267). Outcomes of the other four domains and 
global cognitive function were not aﬀ ected by initial 
plasma total homocysteine concentrations. 
In post-hoc analyses, we examined whether low 
concentrations of vitamin B12 modifi ed the eﬀ ect of folic 
acid supplementation on cognitive performance. Folic 
acid supplementation improved sensorimotor speed 
(diﬀ erence in Z score 0·112, 95% CI 0·001–0·223) and 
information processing speed (0·190, 0·055–0·325) in 
230 participants with initial low or normal concentrations 
of vitamin B12 (<250 pmol/L), but not in 588 participants 
with vitamin B12 concentrations of 250 pmol/L or greater 
(0·046, –0·033 to 0·126 and 0·048, –0·036 to 0·131, 
respectively). 
Folic acid (n=405) Placebo (n=413)
Age (years) 60 (5) 60 (6)
Male 294 (72%) 292 (70%)
High / middle / low education 154 (38%)/144 (36%)/107 (26%) 169 (41%)/168 (41%)/76 (18%)
Mini-mental state examination (points) 29 (28–30) 29 (28– 30)
Range (points) 18–30 15–30
MTHFR 677T allele 0 , 1 , 2* 143 (36%), 187 (46%), 73 (18%) 168 (41%), 191 (46%), 52 (13%)
Vitamin B12 (pmol/L) 290 (239–366) 286 (247–363)
Vitamin B6 (nmol/L)† 37·8 (28·2–49·8) 368·4 (28·2–48·3)
Creatinine (mmol/L) 92·7 (12·5) 92·4 (12·0)
Total cholesterol (mmol/L) 5·8 (1·1) 5·8 (1·1)
LDL cholesterol (mmol/L)† 4·0 (1·0) 4·0 (1·0)
HDL cholesterol (mmol/L) 1·2 (0·3) 1·2 (0·4)
Dyslipidaemia‡ 156 (39%) 138 (33%)
ApoE ε 4 allele, 0 , 1 , 2§ 271 (67%), 122 (30%), 11 (3%) 282 (69%), 116 (28%), 12 (3%)
Systolic blood pressure (mm Hg)* 133 (16) 133 (16)
Diastolic blood pressure (mm Hg)* 77 (8) 77 (9)
Hypertension*¶ 94 (23%) 88 (21%)
Body-mass index|| 26·6 (3·6) 26·5 (3·6)
Current smokers 84 (21%) 83 (20%)
Diabetes mellitus 12 (3%) 14 (3%)
Self-reported cardiovascular disease** 58 (14%) 39 (9%)
MTHFR=methylenetetrahyrdofolate reductase. *Data available for 403 participants in folic acid group and 
411 participants in placebo group. †Data available for 411 participants in placebo group. ‡Total cholesterol 
>6·5 mmol/L, HDL cholesterol <0·9 mmol/L or use of lipid-lowering drugs. §Data available for 403 participants in folic 
acid group and 410 participants in placebo group. ¶Systolic blood pressure ≥160 mm Hg, diastolic blood pressure 
≥95 mm Hg or use of antihypertensive drugs. ||body-mass index=weight in kg divided by the square of the height in 
metres. **Diagnosis of angina pectoris, myocardial infarction, arrhythmia, stroke, or peripheral arterial disease, or 
having undergone angioplasty, coronary bypass surgery, or aortic aneurysm surgery. Data are mean (SD), median (IQR) 
or number (%) unless otherwise indicated.
Table 2: Baseline clinical characteristics 
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Discussion
In 818 older adults, daily oral folic acid supplementation 
for 3 years benefi cially aﬀ ected global cognitive function, 
and specifi cally memory, and information processing: 
functions that are sensitive to ageing.1 The decline in 
memory seen with ageing is generally preceded, and might 
be aﬀ ected, by a decline in speed functions.32 Nonetheless, 
folic acid supplementation might benefi cially aﬀ ect both 
memory and speed simultaneously, since high con-
centrations of homocysteine have been associated with 
atrophy of the hippocampus, an area of the brain which is 
important for memory consolidation.33 Complex speed, a 
domain sensitive to ageing,1 was not aﬀ ected by folic acid 
supplementation. The eﬀ ect of folic acid might be restricted 
to basic aspects of speed and information processing, 
rather than high order information processing. Word 
fl uency was not aﬀ ected by folic acid supplementation, 
perhaps not surprisingly, because encyclopaedic memory 
is a component of crystallised intelligence that stays 
relatively intact as one grows older.34 
Our study might have yielded demonstrable eﬀ ects of 
folic acid on cognitive function because we used sensitive 
tests that exist in parallel versions. We also improved the 
robustness of the underlying cognitive constructs by 
clustering raw test scores for several tests in compound 
performance measures. This procedure decreased 
variation associated with the individual tests. Finally, 
clustering of raw tests scores limited our cognitive 
performance outcomes to fi ve a-priori defi ned outcomes.
By contrast with other trials, we were able to detect an 
eﬀ ect of folic acid on several cognitive functions, for several 
reasons. First, assuming that high plasma total 
homocysteine concentrations are a causal risk factor for 
cognitive decline, we selected a population likely to benefi t 
from folic acid supplementation. Second, we had a fairly 
large study population and supplemented for quite a long 
period. Third, although we did not attempt to measure the 
prevalence of dementia at baseline nor its incidence during 
the duration of the trial, our population is unlikely to have 
included many cognitively impaired or demented 
participants, since the general performance on a dementia 
screening test such as the Mini-Mental State Examination 
was high, both at the beginning and end of the study. That 
treatment with folic acid or other B vitamins might feasibly 
be too late in populations with mild cognitive impairment 
and dementia. Finally, sensitive tests such as our own—not 
the commonly used Mini-Mental State Examination, which 
is a dementia screening device—were needed to detect the 
subtle eﬀ ects of B vitamins on cognitive ageing. Importantly, 
given the general scarcity of positive fi ndings from other 
trials (table 1) and the multiple comparisons made in our 
trial, our results need to be confi rmed by other investigators 
to ascertain whether the signifi cant positive eﬀ ects of folic 
acid on cognitive performance were due to type 1 error.
A strength of our study is the low attrition rate; a high 
attrition rate might have biased our fi ndings of cognitive 
change, since participants with poor cognitive function are 
likely to withdraw from studies.35 In our study, the 
12 participants in the folic acid group and fi ve participants 
in the placebo group who did not return for the end 
measurements had low scores only on baseline tests of 
Folic acid Placebo p 
Serum folate (nmol/L)*
Baseline 12 (9–15) 12 (10–15) ..
Year 1 53 (44–86) 12 (9–15) <0·001
Year 2 50 (42–85) 12 (9–15) <0·001
Year 3 76 (50–103) 13 (10–17) <0·001
Erythrocyte folate (nmol/L)†
Baseline 630 (494–829) 671 (535–815) ..
Year 3 2043 (1741–2469) 697 (546·1–888) <0·001
Dietary folate intake (µg per day)‡
Baseline 192 (159–238) 195 (158–242) ..
Year 3 182 (152–218) 179 (152–224) 0·946
Plasma total homocysteine (µmol/L)§
Baseline 13·0 (11·6–14·7) 12·9 (11·4–14·8) ..
Year 1 9·4 (8·3–10·5) 12·4 (10·7–14·6) <0·001
Year 2 9·6 (8·4–10·9) 12·5 (11·0–15·0) <0·001
Year 3 10·1 (9·0–11·3) 13·4 (11·5–15·2) <0·001
Data are median (IQR). At the time of our study folic acid fortifi cation of foods was prohibited in the Netherlands. 
p values based on non-parametric tests. *At baseline, data available for 405 participants in folic acid group and 
413 participants in placebo group. At Year 1, data available for 397 participants in folic acid group and 407 participants in 
placebo group. At Year 2, data available for 389 participants in folic acid group and 403 participants in placebo group. At 
Year 3, data available for 394 participants in folic acid group and 406 participants in placebo group. †At baseline, data 
available for 405 participants in folic acid group 413 participants in placebo group. At Year 3, data available for 
394 participants in folic acid group and 406 participants in placebo group. ‡At baseline, data available for 
405 participants in folic acid group and 413 participants in placebo group. At Year 3, data available for 394 participants in 
folic acid group and 408 participants in placebo group.  §At baseline, data available for 405 participants in folic acid 
group and 412 participants in placebo group. At Year 1, data available for 397 participants in folic acid group and 
404 participants in placebo group. At Year 2, data available for 390 participants in folic acid group and 404 participants in 
placebo group. At Year 3, data available for 393 participants in folic acid group and 406 participants in placebo group. 
Table 3: Folate status and total homocysteine concentrations throughout the study
Folic acid (n=405) Placebo (n=413)
Word learning test
Total of three immediate recall trials (number of words) 26·9 (5·9) 26·8 (5·4)
Maximum of three immediate recall trials (number of words) 11·2 (2·2) 11·2 (2·0)
Delayed recall (number of words) 8·9 (2·8) 9·0 (2·7)
Concept shifting test
Empty (s)* 5·37 (1·16) 5·43 (1·28)
Numbers (s) 23·26 (5·82) 23·40 (6·07)
Letters (s)† 27·01 (7·40) 27·46 (9·51)
Numbers and letters (s)‡ 35·95 (12·28) 36·34 (13·35)
Stroop colour-word test
Word reading (s)* 16·34 (2·75) 16·38 (3·09)
Naming colour of ink (s)§ 42·62 (10·65) 43·68 (11·79)
Letter digit substitution test, number of digits in 90 s¶ 48·86 (8·96) 48·24 (8·99)
Verbal fl uency test, number of words 24·8 (6·3) 24·1(5·7)
Performance did not diff er between two groups. *Data available for 412 participants in placebo group. †Data available 
for 403 participants in folic acid group and 411 participants in placebo group. ‡Data available for 409 participants in 
placebo group. §Data available for 404 participants in folic acid group and 411 participants in placebo group. ¶Data 
available for 410 participants in placebo group. Data are mean (SD).
Table 4: Performance on cognitive function tests at baseline
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memory (0·558 Z score, 95% CI 0·116–1·000). Their 
absence from year-3 tests is unlikely to have aﬀ ected our 
estimates for several reasons: the eﬀ ect of folic acid 
supplementation on memory was not dependent on 
baseline performance on the memory tests (data not 
shown), the number of participants lost to follow-up was 
minimal, and the eﬀ ect estimates based on participants 
with follow-up data were similar to the intention-to-treat 
analyses. A second strength was the standardised test 
conditions that reduced variation due to factors such as 
caﬀ eine and varying breakfasts.36 
Our study also had some limitations. First, we studied 
participants with high plasma total homocysteine 
concentrations: 3044 out of 4200 participants were 
excluded from the study because of low plasma total 
homocysteine concentrations. Thus, the eﬀ ect of folic 
acid supplement ation on cognitive function might be 
greater than would be expected in populations with lower 
plasma total homo cysteine concentrations—eg, in 
countries such as the USA, with mandated fortifi cation 
of fl our with folic acid. Second, our fi ndings pertain only 
to vitamin B12-replete individuals. Suggestions have 
been made that folic acid supplemen tation exacerbates 
neurological symptoms in people with vitamin B12 
defi ciency.37 The possibility of folic-acid-mediated 
exacerbation of neuropathological dis orders in people 
with low concentrations of vitamin B12 needs to be 
addressed by studies that monitor both vitamin B12 status 
and neurological function. As an improvement to our 
own study, transcobalamin in addition to vitamin B12, 
should be measured, because transcobalamin is a better 
marker of vitamin B12 status than is vitamin B12 itself. 
Will folic acid supplementation lead to a reduced 
incidence of dementia? Whereas some have argued that 
cognitive decline is the beginning of a continuum leading 
to dementia,38 others have argued that the cause of age-
related cognitive decline diﬀ ers from that of dementia39 
and that age-related cognitive decline is not an early state 
of mild cognitive impairment or dementia.2 Cognitive 
tests diﬀ er in their ability to identify individuals who 
worsen to more advanced states such as mild cognitive 
impairment or dementia. Of our test battery, memory is 
the most clinically relevant domain. Memory can be used 
to distinguish between cognitively normal and cognitively 
impaired people.2 Memory storage (delayed recall), in 
particular, can distinguish between people with non-
progressive mild cognitive impairment and preclinical 
Alzheimer’s disease.40 Although folic acid improved 
performance on tests of memory, including delayed 
recall, additional research is needed to determine whether 
folic acid supplementation can reduce the risk of mild 
cognitive impairment or Alzheimer’s disease. 
We have shown that 3-year folic acid supplementation 
improves performance on tests that measure information-
processing speed and memory, domains that are known 
to decline with age, in older adults with raised total 
homocysteine concentrations. Randomised, controlled 
trials are underway to examine the eﬀ ect of homocysteine-
lowering on recurrent vascular disease and cognitive 
function assessed by the Mini-Mental State Examination 
or modifi cations thereof; these and other homocysteine-
lowering trials should include sensitive measures of 
cognitive function. Additionally, trials similar to our own 
should be repeated in other populations to provide 
greater insight into the clinical relevance of folic acid 
supplementation, such as in populations with mild 
cognitive impairment and dementia.
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